- Estimates show that one in three people with type 2 diabetes suffer from chronic kidney disease.
- Both chronic conditions are associated with an increased risk of stroke and heart attack.
- A new study found that drug therapy, already used to treat people with type 2 diabetes or chronic kidney disease, is being used to treat people at risk for heart disease.
These are two separate chronic conditions, but are linked as such One in three adults Type 2 diabetes also has chronic kidney disease.
Furthermore, both conditions are associated with an increased risk of cardiovascular complications, such as stroke and heart attack.
A new study recently published in a journal Lancet Diabetes and EndocrinologyIt turns out that US FDA approved drugs already used to treat people with type 2 diabetes and chronic kidney disease are already in use to treat chronic kidneys at risk of heart disease .
In this study, data were analyzed from Scoring Trialthis was a multicenter clinical trial that included study participants at risk for type 2 diabetes, chronic kidney disease, and heart disease. Study participants received either a placebo or a drug called Sotagliflosin.
“The scored trials examined patients with diabetes, kidney disease, and additional cardiovascular risk due to the known high percentage of cardiac problems faced by these people.” Deepak L. Bhatt, MD, MPH, MBAdirector of Mount Sinai Faster Heart Hospital and Professor Valentin Dr. Faster of Cardiovascular Medicine at Icahn School of Medicine in Mount Sinai, and the lead author of the study, said Today's medical news.
“It had a great advantage in terms of heart failure and adverse kidney events. We wanted to see if it also reduced the risk of heart attacks and stroke,” he said.
In this study, Bhatt and his team analyzed data from almost 10,600 grade test participants who had either Sotagliflozin or placebo between 2017 and 2020 and followed them for about 16 months. .
After analysis, the researchers found that participants taking sotagliflozin reduced the risk of cardiovascular attack, stroke and death by 23% compared to patients taking placebo. I did.
“The benefits occurred within just three months of starting the drug, which is very noteworthy to see such early effects in a stable outpatient population,” Batt said. I said that. “We looked into it separately and found that there was a 32% reduction in heart attacks and a 34% reduction in strokes.”
“People with diabetes or kidney disease are at a very high risk of cardiovascular complications, such as heart attacks and strokes,” he added. “We need new treatments that will help reduce these risks.”
“These receptors are found in the kidneys, intestines, heart and brain,” he explained. “These additional sites of action may explain why sotagliflozin reduces the risk of both heart attack and stroke, and other drugs do not.”
“In patients with diabetes, kidney disease, and additional cardiovascular risk factors, inhibition of SGLT2 and SGLT1 receptors by sotagliflosin reduces the risk of heart failure, kidney disease progression, heart attacks and strokes. This multifaceted view 」
– Deepak L. Bhatt, MD, MPH, MBA
When asked about the next step in this study, Batt said that sotagliflosin should be studied in other populations at high risk of heart attacks and stroke.
“These need to be large and long-term trials, so we need to find someone to fund such research,” he continued. “In the meantime, we have explained the unique ability of STAGLIFLOZIN (among SGLT inhibitor-class drugs) to block the biological effect of blocking SGLT1 receptors, which may reduce the risk of heart attacks and stroke. A smaller basic science experiment is underway to investigate.”
MNT I also had the opportunity to talk Michael Broukhim, MDa board-certified interventional cardiologist at Providence St. John's Health Center in Santa Monica, California, for this study.
“SGLT2 inhibitors have become an important part of the treatment of patients with heart failure,” Broukhim said. “If Sotagliflozin adds the benefits of reducing myocardial infarction and stroke, we recommend using this agent to treat more risk patients.”
“People with type 2 diabetes or kidney disease have a significant increase in risk of heart attacks and stroke despite available treatments. There are additional agents that can reduce the risk of heart and stroke. If this is the case, it will help improve the lives of these high-risk patients.”
– Michael Broukhim, MD
“We would like to look at data that distinguishes the effects of SGLT2 inhibitors and drugs that inhibit both SGLT1 and SGLT2 from more data. The patient population will benefit more than a particular agent.” Broukhim added.